Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Firm Seeks To Prove New Drugs Can Be Developed Cheaply

This article was originally published in PharmAsia News

Executive Summary

An investment company in India has poured more than $61 million into five companies as part of an effort to prove drug development can be done more cheaply than is the practice today. Nadathur Holdings and Investments says it seeks to disprove the assumption new-drug development requires as much as $1 billion. Nadathur has created Lifespring Ventures as a subsidiary, now owner itself of five start-up firms in the drug-discovery process. The firms operate as stand-alone companies trying to find treatments focusing on metabolic syndrome connected to heart, stroke and diabetes conditions. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel